Search
Prenylamine
go.drugbank.com/drugs/DB04825ApprovedWithdrawnPrenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesUrethane
go.drugbank.com/drugs/DB04827ApprovedWithdrawnUrethane, formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 SubstratesFluspirilene
go.drugbank.com/drugs/DB04842ApprovedWithdrawnA long-acting injectable antipsychotic agent used for chronic schizophrenia.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesFebuxostat
go.drugbank.com/drugs/DB04854ApprovedInvestigationalFebuxostat is a non-purine xanthine oxidase (XO) inhibitor. In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout. In the following year, the FDA for ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesDronedarone
go.drugbank.com/drugs/DB04855ApprovedInvestigationalDronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primaril...
Synonyms: N-(2-butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamideCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesDexloxiglumide
go.drugbank.com/drugs/DB04856InvestigationalDexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued. As the D-isomer of loxiglumide, it retains all pharmacological prop...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesLorcaserin
go.drugbank.com/drugs/DB04871ApprovedInvestigationalWithdrawnLorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity. It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesVoacamine
go.drugbank.com/drugs/DB04877ExperimentalVoacamine is an alkaloid isolated from the bark of the Pescheria fuchsiae folia tree. It is an antimalarial drug approved for use in several African countries. Voacamine is also under investigation for use in modulating multidrug-resista...
Categories: P-glycoprotein inhibitorsCalanolide A
go.drugbank.com/drugs/DB04886InvestigationalCalanolide A is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) derived from a plant found in the Malaysian rain forest. A related compound, calanolide B, also has anti-HIV activity. Both drugs are being developed by Sarawak...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBicifadine
go.drugbank.com/drugs/DB04889InvestigationalBicifadine (DOV-220075) is a nonopioid analgesic. It is an inhibitor of both the norepinephrine and serotonin transporters and an NMDA antagonist with a non-narcotic profile. Bicifadine was shown to have potent analgesic activity in vivo...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates